Pneumocystis carinii Pneumonia in Patients in the Developing World Who Have Acquired Immunodeficiency Syndrome

Fisk, David T.; Meshnick, Steven; Kazanjian, Powel H.
January 2003
Clinical Infectious Diseases;1/1/2003, Vol. 36 Issue 1, p70
Academic Journal
We review Pneumocystis carinii pneumonia (PCP) in patients in the developing world (i.e., Africa, Asia, the Philippines, and Central and South America) who have acquired immunodeficiency disease (AIDS). During the first decade of the AIDS pandemic, PCP rarely occurred in African adults. More recent reports have noted that PCP comprises a significantly greater percentage of cases of pneumonia than it did in the past. This trend dramatically contrasts with that observed in industrialized nations, where a reduction in the number of cases of PCP has occurred as a result of the widespread use of primary P. carinii prophylaxis and highly active antiretroviral therapy. Throughout the developing world, the rate of coinfection with Myco-bacterium tuberculosis and PCP is high, ranging from 25% to 80%. Initiation of treatment when PCP is in an advanced stage may account for the high mortality rates (20%-80%) associated with pediatric PCP in the developing world.


Related Articles

  • Management of HIV: still a long way to go. Pozniak, Anton // British Journal of Hospital Medicine (17508460);Mar2008, Vol. 69 Issue 3, p126 

    The article comments on the common illness for patients with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). Its common illness in the developed world was Pneumocystis jirovecii pneumonia (PCP). It stated that pre-highly active antiretroviral therapy (HAART),...

  • Pneumocystis carinii pneumonia.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p26 

    Reports on the US Food and Drug Administration's approval on the marketing of a suspension form of atovaquone in the treatment of pneumocystis carinii pneumonia. Advantages and convenience; Dosage.

  • Pneumocystis pneumonia--Los Angeles.  // MMWR: Morbidity & Mortality Weekly Report;8/30/1996, Vol. 45 Issue 34, p730 

    Reports on Pneumocystis pneumonia cases in Los Angeles, California, from October 1980 to May 1981. Patient profiles; Complications; Statistics.

  • Inhaled or Reduced-Dose Intravenous Pentamidine for Pneumocystis carinii Pneumonia. Conte Jr., John E.; Hollander, Harry; Golden, Jeffrey A. // Annals of Internal Medicine;Oct87, Vol. 107 Issue 4, p495 

    Presents a study which evaluated inhaled or inhaled pentamidine for the treatment of patients with mild Pneumocystis carinii pneumonia. Diagnostic considerations; Methodology of the study; Results.

  • Pneumocystis carinii Pneumonitis. Bradshaw, M.; Myerowitz, R.L.; Schneerson, R.; Whisnant, J.K.; Robbins, J.B. // Annals of Internal Medicine;Nov70, Vol. 73 Issue 5, p775 

    Reviews the clinical presentation, diagnostic procedures, differential diagnosis and complications of Penymocystis carnii pneumonitis.

  • PCP.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1725 

    An encyclopedia entry for the medical acronym "PCP," which stands for phencyclidine hydrochloride, pneumocystis carinii pneumonia, and primary care physician, is presented.

  • Pneumocystis carinii pneumonia as presenting feature of lymphoma. Hill, Lawford; Dean, Paul R. // British Medical Journal (Clinical Research Edition);8/22/1981, Vol. 283 Issue 6290, p527 

    Examines the pneumocystis carinii pneumonia in the cases of lymphoma in Great Britain. Occurrence in immunosuppressed patients; Prevention of transplant rejection; Evidence of oral candidiasis.

  • Pneumocystis carinii Pneumonia in an Immunocompetent Host. Giamarellos-Bourboulis, E.J.; Nikou, G.C.; Petrikkos, G.L.; Mouktaroudi, M.; Toskas, A.; Katsilambros, N. // Clinical Drug Investigation;2003, Vol. 23 Issue 2, p135 

    Presents a case report of Pneumocystis carinii pneumonia in an immunocompetent host. Observation of hypochromic anemia; Observation of pallor and diffuse crepitant rales over both lung fields upon physical examination; Patient's response to intravenous therapy with cotrimoxazole.

  • Etanercept.  // Reactions Weekly;7/3/2010, Issue 1308, p17 

    The article describes the case of a 60-year-old woman who developed pneumocystis jirovecii pneumonia while receiving treatment with etanercept for persistent erosive rheumatoid arthritis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics